Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $81.5500 (0.84%) ($80.4200 - $82.1400) on Fri. Jul. 14, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.69% (three month average) | RSI | 44 | Latest Price | $81.5500(0.84%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE advances 0.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(44%) XBI(43%) IWO(41%) IWC(37%) IWM(37%) | Factors Impacting SAGE price | SAGE will decline at least -1.345% in a week (0% probabilities). VIXM(-11%) UUP(-9%) TLT(-7%) SHY(-4%) IGOV(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.345% (StdDev 2.69%) | Hourly BBV | 0 () | Intraday Trend | 0.6% | | | |
|
5 Day Moving Average | $80.34(1.51%) | 10 Day Moving Average | $80.48(1.33%) | 20 Day Moving Average | $80.86(0.85%) | To recent high | -4% | To recent low | 25.9% | Market Cap | $4.235b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |